The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease
- PMID: 27538418
- DOI: 10.1093/brain/aww162
The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease
Abstract
SEE SCHRAG AND POLITIS DOI101093/AWW190 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: Apathy, which can occur separately or in combination with depression and anxiety, is one of the most frequently encountered neuropsychiatric symptoms in Parkinson's disease. Pathophysiological evidence suggests that parkinsonian apathy is primarily due to a mesolimbic dopaminergic denervation, but the role of the serotonergic alteration has never been examined, despite its well-known involvement in the pathogenesis of depression and anxiety. To fill this gap, we address here the pure model of de novo Parkinson's disease, without the confounding effects of antiparkinsonian treatment. Fifteen apathetic (Lille Apathy Rating Scale scores ≥ -21) and 15 non-apathetic (-36 ≤ Lille Apathy Rating Scale scores ≤ -22) drug-naïve de novo parkinsonian patients were enrolled in the present study and underwent detailed clinical assessment and positron emission tomography imaging, using both dopaminergic [(11)C-N-(3-iodoprop-2E-enyl)-2-beta-carbomethoxy-3-beta-(4-methylphenyl)-nortropane (PE2I)] (n = 29) and serotonergic [(11)C-N,N-dimethyl-2-(-2-amino-4-cyanophenylthio)-benzylamine (DASB)] (n = 27) presynaptic transporter radioligands. Apathetic parkinsonian patients presented higher depression (P = 0.0004) and anxiety (P = 0.004) scores - as assessed using the Beck Depression Inventory and the part B of the State-Trait Anxiety Inventory, respectively - compared to the non-apathetic ones - who were not different from the age-matched healthy subjects (n = 15). Relative to the controls, the non-apathetic parkinsonian patients mainly showed dopaminergic denervation (n = 14) within the right caudate nucleus, bilateral putamen, thalamus and pallidum, while serotonergic innervation (n = 15) was fairly preserved. Apathetic parkinsonian patients exhibited, compared to controls, combined and widespread dopaminergic (n = 15) and serotonergic (n = 12) degeneration within the bilateral caudate nuclei, putamen, ventral striatum, pallidum and thalamus, but also a specific bilateral dopaminergic disruption within the substantia nigra-ventral tegmental area complex, as well as a specific serotonergic alteration within the insula, the orbitofrontal and the subgenual anterior cingulate cortices. When comparing the two parkinsonian groups, the apathetic patients mainly displayed greater serotonergic alteration in the ventral striatum, the dorsal and the subgenual parts of the anterior cingulate cortices, bilaterally, as well as in the right-sided caudate nucleus and the right-sided orbitofrontal cortex. Regression analyses also revealed that the severity of apathy was moreover mainly related to specific serotonergic lesions within the right-sided anterior caudate nucleus and the orbitofrontal cortex, while the degree of both depression and anxiety was primarily linked to serotonergic disruption within the bilateral subgenual parts and/or the right dorsal part of the anterior cingulate cortex, without prominent role of the dopaminergic degeneration in the pathogenesis of these three non-motor signs. Altogether, these findings highlight a prominent role of the serotonergic degeneration in the expression of the neuropsychiatric symptoms occurring at the onset of Parkinson's disease.
Keywords: apathy; depression; dopamine; drug-naïve de novo Parkinson’s disease; serotonin.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Comment in
-
Serotonergic loss underlying apathy in Parkinson's disease.Brain. 2016 Sep;139(Pt 9):2338-9. doi: 10.1093/brain/aww190. Brain. 2016. PMID: 27559106 No abstract available.
Similar articles
-
Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs.Mov Disord. 2021 Dec;36(12):2888-2900. doi: 10.1002/mds.28722. Epub 2021 Sep 8. Mov Disord. 2021. PMID: 34494685
-
Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.Curr Neurol Neurosci Rep. 2017 Aug 18;17(10):76. doi: 10.1007/s11910-017-0788-0. Curr Neurol Neurosci Rep. 2017. PMID: 28822071 Review.
-
Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.Brain. 2010 Apr;133(Pt 4):1111-27. doi: 10.1093/brain/awq032. Epub 2010 Mar 17. Brain. 2010. PMID: 20237128 Clinical Trial.
-
Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease.Mov Disord. 2022 Jun;37(6):1211-1221. doi: 10.1002/mds.28971. Epub 2022 Mar 3. Mov Disord. 2022. PMID: 35238430
-
Imaging in Parkinson's disease: the role of monoamines in behavior.Biol Psychiatry. 2006 May 15;59(10):908-18. doi: 10.1016/j.biopsych.2005.12.017. Epub 2006 Apr 11. Biol Psychiatry. 2006. PMID: 16581032 Review.
Cited by
-
Cardiovascular dysautonomia and cognitive impairment in Parkinson's disease (Review).Med Int (Lond). 2024 Sep 19;4(6):70. doi: 10.3892/mi.2024.194. eCollection 2024 Nov-Dec. Med Int (Lond). 2024. PMID: 39355336 Free PMC article. Review.
-
The pathobiological basis of depression in Parkinson disease: challenges and outlooks.J Neural Transm (Vienna). 2022 Dec;129(12):1397-1418. doi: 10.1007/s00702-022-02559-5. Epub 2022 Nov 2. J Neural Transm (Vienna). 2022. PMID: 36322206 Free PMC article. Review.
-
Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.Mov Disord. 2022 Nov;37(11):2301-2307. doi: 10.1002/mds.29220. Epub 2022 Sep 14. Mov Disord. 2022. PMID: 36102173 Free PMC article.
-
Analysis of Influencing Factors of Apathy in Patients with Parkinson's Disease.Brain Sci. 2022 Oct 4;12(10):1343. doi: 10.3390/brainsci12101343. Brain Sci. 2022. PMID: 36291277 Free PMC article.
-
Hot and Cold Cognitive Disturbances in Parkinson Patients Treated with DBS-STN: A Combined PET and Neuropsychological Study.Brain Sci. 2022 May 16;12(5):654. doi: 10.3390/brainsci12050654. Brain Sci. 2022. PMID: 35625040 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous